Nancy Stagliano is Director at Pandion Therapeutics, Inc. (PAND). They have made 1 open-market trade across 1 company since 2020, most recently 2021-04-01.
CIK 0001817449
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $18K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PAND | 1,000 | $60K |
Shares reported on the most recent Form 4, priced at the 2020-07-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PAND | BUY | 2020-07-21 | 2020-07-21 | $18.00 | $18K | -6.7% | -2.2% | -38.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.